CUREVAC N.V. O.N.
Commented by Carsten Mainitz on June 14th, 2021 | 11:04 CEST
Adler Modemärkte, Barsele Minerals, CureVac - Watch out: The ABC of price rockets!
News is the fuel for prices. The only question is in which direction the prices will go and how long the fuel will last. With the prospect of a loan from the federal government, the shares of the insolvent textile retailer Adler Modemärkte have made substantial gains since mid-May. In the last week, there was also news at Barsele Minerals and CureVac, which should move the prices in the next few days!
Read
Commented by André Will-Laudien on June 7th, 2021 | 08:32 CEST
CureVac, Cardiol Therapeutics, Formycon, NanoRepro - Pharma stocks with potential!
In Germany, around 231,000 people died as a result of cancer in 2019. As reported by the Federal Statistical Office, cancer was the cause of a quarter of all deaths. This proportion has hardly changed within 20 years, even though the number of cancer deaths has increased by around 10% since 1999. The precise number 1 cause of widespread disease in Germany is cardiovascular disease, such as heart failure, coronary heart disease and myocardial infarction. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. So research continues to be in demand. We look at interesting representatives of the industry.
Read
Commented by Nico Popp on June 1st, 2021 | 10:05 CEST
Defence Therapeutics, CureVac, BioNTech: Vaccine against cancer makes progress
Biotechnology is the map to the holy grail that needs to be found as quickly as possible for many sick people. When the pandemic broke out last year, it accelerated some developments. For example, mRNA technology, which BioNTech and CureVac had already been researching, was successfully launched as a vaccine technology. It is well known that this can be used to develop effective vaccines against coronaviruses and target diseases such as cancer. BioNTech has this option in mind and holds good cards to succeed with it. The young biotech startup Defence Therapeutics has also recently reported its first successes in the fight against cancer.
Read
Commented by Stefan Feulner on May 27th, 2021 | 10:13 CEST
CureVac, NSJ Gold, Steinhoff - New opportunities every day
Following a performance of over 15% since the start of the year, the DAX seems to be running out of steam around the 15,500 mark. At least a short correction would be more than due here and only healthy to tackle the next barriers to the top. Gold was able to break through the USD 1,900 mark for the first time this year. It should now be a done deal that the correction that has been underway since August has come to an end. The general conditions of rising inflation fears and the further loose monetary policy of the central banks should soon help the precious yellow metal to new highs.
Read
Commented by Stefan Feulner on May 19th, 2021 | 08:39 CEST
CureVac, The Place Holdings, TUI - New start with great potential!
Finally! Due to the positive development of the vaccination program and the successful testing strategy, the incidence figures in Germany are gradually decreasing. Industries that suffered heavily from the pandemic, such as tourism and air travel, are breathing a sigh of relief. While Germans are still planning more domestic vacations during the Whitsun vacations, bookings abroad for the summer are rising disproportionately. Other countries are also increasingly focusing on domestic tourism, with considerable potential for the respective operators.
Read
Commented by André Will-Laudien on May 12th, 2021 | 09:36 CEST
Formycon, NanoRepro, CureVac, PsyBio Therapeutics - Beat Corona with these stocks!
The vaccination rate is moving steadily forward in Europe. The European Commission has ordered another 2 billion doses from BioNTech. After all the squabbling over AstraZeneca, that may not be a bad decision. But the successors in this market will soon be on the starting blocks. CureVac is close to the approval of its vaccine, and Formycon is making a push with a therapy. NanoRepro, a Company based in Marburg, Germany, wants to bring a highly valid antigen test to market that can give those already vaccinated clear information about the body's immune defenses. The pace in the health sector could not be higher at the moment.
Read
Commented by Stefan Feulner on May 10th, 2021 | 09:14 CEST
CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!
The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.
Read
Commented by Nico Popp on May 3rd, 2021 | 07:25 CEST
BioNTech, CureVac, Cardiol Therapeutics: In on the next blockbuster from the start
The two German companies BioNTech and CureVac, have been causing quite a stir since the outbreak of the pandemic. At first, the biotech newcomers were known only to hard-nosed investors who are used to seizing long-term opportunities and accepting initial uncertainty to do so. Even during the first months of the pandemic, it was far from clear whether BioNTech and CureVac would be successful. Only a few insiders had the right instinct early on thanks to the necessary background knowledge and are pleased with BioNTech's annual performance of 260%. But what characterizes the success of innovative biotech companies? And where are the next opportunities lurking? We outline some exciting investment stories.
Read
Commented by Stefan Feulner on April 28th, 2021 | 07:04 CEST
CureVac, PsyBio, Evotec - Revolution in the billion-dollar market!
The anxiety and limitations associated with the coronavirus pose major challenges for people suffering from depression. Officially, around 350 million people worldwide live with depression, but the number of unreported cases is significantly higher. At the moment, the number one cause of the disease is only combated with antidepressants; there are hardly any alternative treatment methods without severe side effects. A completely new field is currently emerging that could completely eclipse existing drugs, with incredible potential for the young companies.
Read
Commented by Stefan Feulner on April 20th, 2021 | 09:45 CEST
Varta, Sierra Growth, CureVac - Clear signals!
Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.
Read